Compare Becton Dickinson and Co (BDX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Johnson Controls International PLC — how do they compare? Becton Dickinson and Co trades at $178.91 (market cap $49.41B), while Johnson Controls International PLC trades at $155.77 (market cap $93.74B). The key difference: Johnson Controls International PLC is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| BDX | JCI | |
|---|---|---|
Market Cap | $49.41B | $93.74B |
Sector | Health | Industrials |
52-Week High | $185.39 | $154.76 |
52-Week Low | $138.62 | $103.52 |
Enterprise Value | $65.51B | $102.58B |
Dividend Yield | 2.32% | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
JCI trades at $150.70, down 0.99% on the day, with a strong bullish technical signal from moving averages. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by double-digit organic sales growth and record backlog. Analyst consensus is strongly positive with a $168.25 price target and no sell ratings. Recent news highlights efficiency leadership and AI-related thermal management innovations.
The outlook remains favorable given earnings momentum and strategic positioning in high-demand sectors like data centers. Key risks include execution on growth targets and macroeconomic sensitivity. The stock presents a growth opportunity supported by fundamental strength and bullish sentiment, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
